tradingkey.logo
tradingkey.logo
검색

Taysha Gene Therapies Inc

TSHA
관심 목록에 추가
4.100USD
-0.110-2.61%
종가 11-13 16:00(ET)
1.34B시가총액
손실P/E TTM

Taysha Gene Therapies Inc 정보 회사

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.

Taysha Gene Therapies Inc 프로필

종목 코드 TSHA
회사 이름Taysha Gene Therapies Inc
상장일Sep 24, 2020
CEONolan (Sean Patrick)
직원 수73
유형Ordinary Share
회계 연도 종료Sep 24
주소3000 Pegasus Park Drive
도시DALLAS
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호75247
전화12146120000
웹사이트https://tayshagtx.com/
종목 코드 TSHA
상장일Sep 24, 2020
CEONolan (Sean Patrick)

Taysha Gene Therapies Inc의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Mr. Sean Patrick Nolan
Mr. Sean Patrick Nolan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
638.54K
-76.53%
Mr. Sean Patrick Nolan
Mr. Sean Patrick Nolan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
638.54K
-76.53%
Mr. Sean Patrick Nolan
Mr. Sean Patrick Nolan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
638.54K
-76.53%
Mr. Kamran Alam
Mr. Kamran Alam
Chief Financial Officer
Chief Financial Officer
461.56K
-21.78%
Mr. Kamran Alam
Mr. Kamran Alam
Chief Financial Officer
Chief Financial Officer
461.56K
-21.78%
Mr. Kamran Alam
Mr. Kamran Alam
Chief Financial Officer
Chief Financial Officer
461.56K
-21.78%
Dr. Laura Sepp-Lorenzino, Ph.D.
Dr. Laura Sepp-Lorenzino, Ph.D.
Independent Director
Independent Director
70.56K
+30.24%
Dr. Laura Sepp-Lorenzino, Ph.D.
Dr. Laura Sepp-Lorenzino, Ph.D.
Independent Director
Independent Director
70.56K
+30.24%
Dr. Laura Sepp-Lorenzino, Ph.D.
Dr. Laura Sepp-Lorenzino, Ph.D.
Independent Director
Independent Director
70.56K
+30.24%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
President, Head of Research and Development, Director
President, Head of Research and Development, Director
34.23K
-528.78%
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Sean Patrick Nolan
Mr. Sean Patrick Nolan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
638.54K
-76.53%
Mr. Sean Patrick Nolan
Mr. Sean Patrick Nolan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
638.54K
-76.53%
Mr. Sean Patrick Nolan
Mr. Sean Patrick Nolan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
638.54K
-76.53%
Mr. Kamran Alam
Mr. Kamran Alam
Chief Financial Officer
Chief Financial Officer
461.56K
-21.78%
Mr. Kamran Alam
Mr. Kamran Alam
Chief Financial Officer
Chief Financial Officer
461.56K
-21.78%
Mr. Kamran Alam
Mr. Kamran Alam
Chief Financial Officer
Chief Financial Officer
461.56K
-21.78%

자주 묻는 질문

Taysha Gene Therapies Inc의 상위 5대 주주는 누구인가요?

Taysha Gene Therapies Inc의 상위 5대 주주는 다음과 같습니다: Mr. Sean Patrick Nolan

Taysha Gene Therapies Inc(TSHA)의 주식을 보유한 기관은 몇 개입니까?

2026Q1 기준으로, Taysha Gene Therapies Inc의 주식을 보유한 기관은 총 369곳이며, 이들이 보유한 주식의 총 가치는 약 287.49M로 전체 발행 주식의 100.06%를 차지합니다. 이는 2025Q4 대비 5517242.00 증가한 수치입니다.
tradingkey.logo
위험 경고: 저희 웹사이트와 모바일 앱은 특정 투자 상품에 대한 일반적인 정보만을 제공합니다. Finsights는 재정적 조언이나 투자 상품에 대한 추천을 제공하지 않으며, 이러한 정보 제공이 Finsights가 금융 조언이나 추천을 제공하는 것으로 해석되어서는 안 됩니다.
투자 상품은 투자 원금 손실을 포함한 상당한 투자 위험에 노출되어 있으며, 모든 사람에게 적합하지 않을 수 있습니다. 투자 상품의 과거 성과는 미래 성과를 보장하지 않습니다.
Finsights는 제3자 광고주나 제휴사가 저희 웹사이트나 모바일 앱 또는 그 일부에 광고를 게재하거나 전달할 수 있도록 허용할 수 있으며, 사용자가 광고와 상호작용하는 방식에 따라 이들로부터 보상을 받을 수 있습니다.
© 저작권: FINSIGHTS MEDIA PTE. LTD. 모든 권리 보유